Nocardiosis
A serious, slow-growing bacterial infection that typically starts in the lungs and can spread to the brain, mostly affecting people with weakened immune systems.
Emergency Management: Brain herniation from a rapidly expanding intracranial abscess. Requires emergent neurosurgical decompression and high-dose IV corticosteroids (though steroids are otherwise avoided in this infection).
Nocardiosis is a localized or disseminated infection caused by species of the genus Nocardia, which are ubiquitous, aerobic, weakly Gram-positive, partially acid-fast branching bacilli found in soil and water. It primarily behaves as an opportunistic infection, most commonly affecting the lungs (pulmonary nocardiosis) in immunocompromised patients, with a high propensity to disseminate hematogenously to the central nervous system (CNS).
Detailed Overview
Nocardia avoids intracellular killing by macrophages through inhibiting phagosome-lysosome fusion and neutralizing reactive oxygen species. Because it relies heavily on cell-mediated immunity for clearance, patients with deficits in T-cell function (e.g., solid organ transplant recipients, those on high-dose corticosteroids, or HIV/AIDS) are at severe risk. The clinical presentation is often subacute and can mimic tuberculosis or malignancy on imaging. Without prolonged, targeted antibiotic therapy, mortality in disseminated cases is exceptionally high.
Epidemiology & Demographics
Incidence is rare in the general population but significant in the immunocompromised (estimated 500-1000 cases annually in the US). More common in males. It is a leading bacterial cause of opportunistic brain abscesses in transplant recipients.
Etiological Mechanism
Caused by various Nocardia species. Nocardia asteroides complex (including N. cyriacigeorgica and N. farcinica) is responsible for most pulmonary and systemic disease. Nocardia brasiliensis is the most common cause of primary cutaneous nocardiosis.
Primary Causes
Infection primarily occurs via inhalation of aerosolized bacteria from the environment (soil/dust), leading to pulmonary infection. Direct inoculation through broken skin leads to primary cutaneous disease.
Upon inhalation, Nocardia is phagocytosed by alveolar macrophages but resists intracellular destruction via production of catalase and superoxide dismutase, and by preventing phagosome acidification. It induces a suppurative necrosis (abscess formation) with prominent neutrophil infiltration. From the lungs, Nocardia readily invades pulmonary venules, disseminating via the bloodstream. It has a striking tropism for neural tissue, crossing the blood-brain barrier to form single or multiloculated brain abscesses.
Diagnostic Criteria & Guidelines
Requires isolation and identification of Nocardia from clinical specimens (sputum, BAL, abscess aspirate, blood). Growth is slow (requires 2-14 days). Speciation and susceptibility testing are mandatory due to highly variable resistance patterns among species.
For severe or disseminated disease: Induction with 2-3 IV drugs. Trimethoprim-sulfamethoxazole (TMP-SMX) 15 mg/kg/day IV (TMP component) PLUS Imipenem 500 mg IV every 6 hours PLUS Amikacin 15 mg/kg IV daily. For mild/cutaneous disease: TMP-SMX monotherapy orally.
Second-Line & Adjunctive Therapy
For sulfonamide allergy or resistance: Linezolid 600 mg IV/PO BID is highly active against almost all Nocardia species and has excellent CNS penetration. Ceftriaxone, Cefotaxime, or Minocycline are other alternatives based on susceptibility testing.
Surgical & Procedural Management
Neurosurgical stereotactic aspiration or excision of large (>2.5 cm) or accessible brain abscesses. Video-assisted thoracoscopic surgery (VATS) or chest tube for pleural empyema.
Patient Counseling & Advice
Warn the patient that therapy is exceptionally long (often 6 to 12 months) and adherence is critical to prevent fatal relapse. Explain that the medication may have significant side effects (like kidney issues from TMP-SMX) requiring frequent blood tests.
Follow-Up & Monitoring Schedule
Monthly clinical follow-up. Repeat CT chest and MRI brain every 1-3 months to document radiological resolution before stopping therapy. Close monitoring of renal function and CBC while on high-dose TMP-SMX.
Preventive Strategies
Standard TMP-SMX prophylaxis used for Pneumocystis (PCP) in transplant/HIV patients (e.g., 1 DS tablet daily or thrice weekly) also provides effective prophylaxis against Nocardia.
Cutaneous nocardiosis: >95% cure rate. Pulmonary nocardiosis: 10-20% mortality. Disseminated/CNS nocardiosis: 30-50% mortality, especially in highly immunosuppressed patients.